Clinical Trials

28 enrolled

Phase EARLY_PHASE1 Completed

Carcinoma, Renal Cell, Wilms Tumor

NCT04028245 2026-04-15

SPARC-1

17 enrolled

Carcinoma, Renal Cell

NCT05047965 2026-04-15

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

65 enrolled

Prostatic Neoplasms

NCT07516704 2026-04-08

Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study

94 enrolled

Prostatic Neoplasms

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Carcinoma, Renal Cell

NCT05477823 2026-03-20

Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer

Prostatic Neoplasms

NCT04857502 2026-03-13

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

NCT01804712 2026-03-12

Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy

8 enrolled 12 charts

Neoplasms, Prostatic Neoplasms

NCT07468708 2026-03-12

The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

Prostatic Neoplasms

NCT07164027 2026-03-10

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Prostatic Neoplasms

NCT05045066 2026-03-02

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients

220 enrolled

Prostatic Neoplasms

NCT06759701 2026-02-27

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

Diabetes Mellitus, Prostatic Neoplasms

NCT07439120 2026-02-27

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

10 enrolled

Carcinoma, Transitional Cell

NCT03334500 2026-02-20

Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer

Prostatic Neoplasms

NCT03861676 2026-02-13

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT

20 enrolled

Prostatic Neoplasms

NCT05683964 2026-02-13

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

9 enrolled

Prostatic Neoplasms

NCT05160597 2026-02-12

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Prostatic Neoplasms

NCT07389174 2026-02-05

Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

40 enrolled

mHSPC

NCT06408298 2026-02-04

HCQ in Resectable Localized Prostate Cancer

20 enrolled

Resectable Localized Prostate Cancer

NCT06888102 2026-02-03

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

20 enrolled

High-risk Prostate Cancer

NCT07381582 2026-02-02

161Tb-LNC1011

15 enrolled

Prostatic Neoplasms

NCT06318871 2026-01-29

Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

10 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

NCT04018053 2026-01-27

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

16 enrolled 3 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07156045 2026-01-23

Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer

10 enrolled

Prostate Cancer Castration-resistant Prostate Cancer

NCT07298239 2026-01-22

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castration-resistant Prostate Cancer (mCRPC)

15 enrolled